Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia

References

• Hansson R, Forbes HJ, Langan SM, et al. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116(12):1643–1651.
   PubMed Web of Science ®Google Scholar
• Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340–346.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Lonnqvist B, Gahrton G, et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis. 1986;153(5):840–847.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Kim HW, Flowers MED, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800–1805.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110(8):3071–3077.
   PubMed Web of Science ®Google Scholar
• Baden LP, Swaminathan S, Almyroudis NG, et al. Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network. Version 1. 2020. [cited 2020 May 27]. Available from: www.nccn.org.
   Google Scholar
• Sandherr M, Hentrich M, von Lilienfeld-Toal M, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies-update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94(9):1441–1450.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Hutchinson J. Herpes caused by arsenic. Med Times. St Bartol Hosp Rep. 1868;9.
   Google Scholar
• Nielson L. On the appearance of herpes zoster during administration of arsenic. Selected monographs on dermatology. New Syndenham Soc. 1893;143:167–175.
   Google Scholar
• Reynolds ES. An account of the epidemic outbreak of arsenic poisoning occurring in beer drinkers in the north of England and the midland counties in 1900. Med Chir Trans. 1901;84:409–452.
   PubMedGoogle Scholar
• Lanska DJ. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004;83(6):408.
   PubMed Web of Science ®Google Scholar
• Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005;53(5):890–892.
   PubMed Web of Science ®Google Scholar
• Cardenas A, Smit E, Houseman A, et al. Arsenic exposure and prevalence of the varicella zoster virus in the United States: NHANES (2003-2004 and 2009-2010). Environ Health Perspect. 2015;123(6):590–596.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–1580.
   PubMed Web of Science ®Google Scholar
• Glass JL, Kishtagari A, Douer D, et al. Herpes zoster is more frequent in patients receiving higher cumulative doses of arsenic trioxide and is mitigated by prophylactic acyclovir. Blood. 2015;126(23):3752–3752.
   Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Shigeno K, et al. Arsenic trioxide inhibited bacterial growth but increased the incidence of herpes zoster among patients with APL; results from in vitro and clinical studies. Blood. 2006;108(11):4559–4559.
   Web of Science ®Google Scholar
• Yamakura M, Tsuda K, Ugai T, et al. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia. Acta Haematol. 2014;131(2):76–77.
   PubMed Web of Science ®Google Scholar
• Au WY, Kumana CR, Lee HKK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118(25):6535–6543.
   PubMed Web of Science ®Google Scholar
• Nouri K, Riccotti CA, Bouzari N, et al. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol. 2006;5:182–185.
   PubMedGoogle Scholar
• Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol. 2007;46(4):557–561.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Larghero J, Arnulf B, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia. 2004;18(9):1518–1521.
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004;83(3):198–200.
   PubMed Web of Science ®Google Scholar
• Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, et al. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ. 1995;310(6988):1169–1172.
   PubMed Web of Science ®Google Scholar
• Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, et al. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1997;15(6):2269–2274.
   PubMed Web of Science ®Google Scholar
• Zostavax [prescribing information]. Whitehouse Station (NJ): Merck & Co, Inc; 2019.
   Google Scholar
• Shingrix [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2019.
   Google Scholar
• Harrison MT, McCoy KL. Immunosuppression by arsenic: a comparison of cathepsin L inhibition and apoptosis. Int Immunopharmacol. 2001;1(4):647–656.
   PubMed Web of Science ®Google Scholar
• Cheng HY, Li P, David M, et al. Arsenic inhibition of the JAK-STAT pathway. Oncogene. 2004;23(20):3603–3612.
   PubMed Web of Science ®Google Scholar
• Xu H, Lauer F, Liu KJ, et al. Environmentally relevant concentrations of arsenite and monomethylarsonous acid inhibit IL-7/STAT5 cytokine signaling pathways in mouse CD3 + CD4-CD8- double negative thymus cells. Toxicol Lett. 2016;247:62–68.
   PubMed Web of Science ®Google Scholar
• Vega L, Ostrosky-Wegman P, Fortoul TI, et al. Sodium arsenite reduces proliferation of human activated T-cells by inhibition of the secretion of interleukin-2. Immunopharmacol Immunotoxicol. 1999;21(2):203–220.
   PubMed Web of Science ®Google Scholar
• Biswas R, Ghosh P, Banerjee N, et al. Analysis of T-cell proliferation and cytokine secretion in the individuals exposed to arsenic. Hum Exp Toxicol. 2008;27(5):381–386.
   PubMed Web of Science ®Google Scholar
• Banerjee N, Banerjee S, Sen R, et al. Chronic arsenic exposure impairs macrophage functions in the exposed individuals. J Clin Immunol. 2009;29(5):582–594.
   PubMed Web of Science ®Google Scholar
• Haque R, Chaudhary A, Sadaf N. Immunomodulatory role of arsenic in regulatory T cells. Endocr Metab Immune Disord Drug Targets. 2017;17(3):176–181.
   PubMed Web of Science ®Google Scholar